XOMA Royalty (XOMA) Receivables - Net (2010 - 2026)
XOMA Royalty (XOMA) reported Receivables - Net of $4.6 million for Q1 2026, down 17.12% on a YoY basis from $5.5 million in Q1 2025, and up 1570.91% sequentially from $275000.0 in Q3 2025.
XOMA Royalty (XOMA) Receivables - Net (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Receivables - Net data on file, last reported at $4.6 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Net fell 17.12% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (down 17.12% YoY), and the FY2025 full-year result was $4.9 million, up 166.23% from the prior year.
- Receivables - Net advanced to $4.6 million in Q1 2026, from $275000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $5.5 million in Q1 2025 to a low of $3000.0 in Q1 2024.
- A 5-year average of $1.1 million and a median of $275000.0 in 2025 frame the typical range for Receivables - Net.
- Across the five-year window, Receivables - Net tumbled 96.91% in 2022 and surged 184700.0% in 2025, its largest moves.
- Tracing XOMA's Receivables - Net over 5 years: stood at $16000.0 in 2022, then soared by 168.75% to $43000.0 in 2023, then surged by 2330.23% to $1.0 million in 2024, then plunged by 73.68% to $275000.0 in 2025, then jumped by 1570.91% to $4.6 million in 2026.
- Business Quant data shows XOMA's Receivables - Net at $4.6 million in Q1 2026, $275000.0 in Q3 2025, and $1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.60 Mn |
| Mar 31, 2026 | 4.60 Mn |
| Sep 17, 2025 | 275,000.00 |
| Sep 17, 2025 | 275,000.00 |
| Jun 30, 2025 | 1.82 Mn |
| Jun 30, 2025 | 1.82 Mn |
| Mar 31, 2025 | 5.54 Mn |
| Mar 31, 2025 | 5.54 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 526,000.00 |
| Jun 30, 2024 | 526,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Sep 30, 2023 | 43,000.00 |
| Sep 30, 2023 | 43,000.00 |
| Jun 30, 2023 | 901,000.00 |
| Jun 30, 2023 | 901,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Mar 31, 2023 | 6,000.00 |